Literature DB >> 17403766

The economic burden of complications during percutaneous coronary intervention.

Kurt M Jacobson1, Kirsten Hall Long, Erin K McMurtry, James M Naessens, Charanjit S Rihal.   

Abstract

BACKGROUND: Technological advances have enabled percutaneous coronary intervention (PCI) to be applied with expanding indications. However, escalating costs are of concern. This study assessed the incremental medical costs of major in-hospital procedural complications incurred by patients undergoing PCI.
METHODS: We considered all patients undergoing elective, urgent, or emergent PCI at Mayo Clinic Rochester between 3/1/1998-3/31/2003 in analyses. Clinical, angiographic, and outcome data were derived from the Mayo Clinic PCI Registry. In-hospital PCI complications included major adverse cardiac and cerebrovascular events (MACCE) and bleeding of clinical significance. Administrative data were used to estimate total costs in standardised, year 2004, constant-US dollars. We used generalised linear modeling to estimate costs associated with complications adjusting for baseline and procedural characteristics.
RESULTS: 1071 (13.2%) of patients experienced complications during hospitalisation. Patients experiencing complications were older, more likely to present with emergent PCI, recent or prior myocardial infarction, multi-vessel disease, and comorbid conditions than patients who did not experience these events. Unadjusted total costs were, on average, $27,865+/-$39,424 for complicated patient episodes compared to $12,279+/-$6796 for episodes that were complication free (p<0.0001). Adjusted mean costs were $6984 higher for complicated PCIs compared with uncomplicated PCI episodes (95% CI of cost difference: $5801, $8168). Incremental costs associated with isolated bleeding events, MACCE, or for both bleeding and MACCE events were $5883, $5086, and $15,437, respectively (p<0.0001).
CONCLUSIONS: This high-volume study highlights the significant economic burden associated with procedural complications. Resources and systems approaches to minimising clinical and economic complications in PCI are warranted.

Entities:  

Mesh:

Year:  2007        PMID: 17403766      PMCID: PMC2653156          DOI: 10.1136/qshc.2006.019331

Source DB:  PubMed          Journal:  Qual Saf Health Care        ISSN: 1475-3898


  41 in total

1.  Reducing costs and improving outcomes of percutaneous coronary interventions.

Authors:  Mauro Moscucci; David W Muller; Charles M Watts; Vinita Bahl; Eric R Bates; Steven W Werns; Eva Kline-Rogers; Dean Karavite; Kim A Eagle
Journal:  Am J Manag Care       Date:  2003-05       Impact factor: 2.229

2.  Correlates of procedural complications and a simple integer risk score for percutaneous coronary intervention.

Authors:  Mandeep Singh; Ryan J Lennon; David R Holmes; Malcolm R Bell; Charanjit S Rihal
Journal:  J Am Coll Cardiol       Date:  2002-08-07       Impact factor: 24.094

3.  Multiple regression of cost data: use of generalised linear models.

Authors:  Julie Barber; Simon Thompson
Journal:  J Health Serv Res Policy       Date:  2004-10

4.  Use of continuous quality improvement to increase use of process measures in patients undergoing coronary artery bypass graft surgery: a randomized controlled trial.

Authors:  T Bruce Ferguson; Eric D Peterson; Laura P Coombs; Mary C Eiken; Meghan L Carey; Frederick L Grover; Elizabeth R DeLong
Journal:  JAMA       Date:  2003-07-02       Impact factor: 56.272

5.  Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions.

Authors:  Timothy D Kinnaird; Eugenio Stabile; Gary S Mintz; Cheol Whan Lee; Daniel A Canos; Natalie Gevorkian; Ellen E Pinnow; Kenneth M Kent; Augusto D Pichard; Lowell F Satler; Neil J Weissman; Joseph Lindsay; Shmuel Fuchs
Journal:  Am J Cardiol       Date:  2003-10-15       Impact factor: 2.778

6.  A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease.

Authors:  Gregg W Stone; Stephen G Ellis; David A Cox; James Hermiller; Charles O'Shaughnessy; James Tift Mann; Mark Turco; Ronald Caputo; Patrick Bergin; Joel Greenberg; Jeffrey J Popma; Mary E Russell
Journal:  N Engl J Med       Date:  2004-01-15       Impact factor: 91.245

7.  A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.

Authors:  Marie-Claude Morice; Patrick W Serruys; J Eduardo Sousa; Jean Fajadet; Ernesto Ban Hayashi; Marco Perin; Antonio Colombo; G Schuler; Paul Barragan; Giulio Guagliumi; Ferenc Molnàr; Robert Falotico
Journal:  N Engl J Med       Date:  2002-06-06       Impact factor: 91.245

8.  Economic impact of drug-eluting stents on hospital systems: a disease-state model.

Authors:  David F Kong; Eric L Eisenstein; Michael H Sketch; James P Zidar; Thomas J Ryan; Robert A Harrington; Mark F Newman; Peter K Smith; Daniel B Mark; Robert M Califf
Journal:  Am Heart J       Date:  2004-03       Impact factor: 4.749

9.  Percutaneous transluminal coronary angioplasty: current status and future trends.

Authors:  D R Holmes; R E Vlietstra
Journal:  Mayo Clin Proc       Date:  1986-11       Impact factor: 7.616

10.  Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.

Authors:  Jeffrey W Moses; Martin B Leon; Jeffrey J Popma; Peter J Fitzgerald; David R Holmes; Charles O'Shaughnessy; Ronald P Caputo; Dean J Kereiakes; David O Williams; Paul S Teirstein; Judith L Jaeger; Richard E Kuntz
Journal:  N Engl J Med       Date:  2003-10-02       Impact factor: 91.245

View more
  7 in total

1.  The volume-outcome relationship in laparoscopic cholecystectomy: a population-based study using propensity score matching.

Authors:  Hon-Yi Shi; King-Teh Lee; Chong-Chi Chiu; Hao-Hsien Lee
Journal:  Surg Endosc       Date:  2013-04-26       Impact factor: 4.584

2.  Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel.

Authors:  Emily S Reese; C Daniel Mullins; Amber L Beitelshees; Eberechukwu Onukwugha
Journal:  Pharmacotherapy       Date:  2012-04       Impact factor: 4.705

3.  Costs of venous thromboembolism associated with hospitalization for medical illness.

Authors:  Kevin P Cohoon; Cynthia L Leibson; Jeanine E Ransom; Aneel A Ashrani; Tanya M Petterson; Kirsten Hall Long; Kent R Bailey; Johm A Heit
Journal:  Am J Manag Care       Date:  2015-04-01       Impact factor: 2.229

4.  Impact of bleeding-related complications and/or blood product transfusions on hospital costs in inpatient surgical patients.

Authors:  Michael E Stokes; Xin Ye; Manan Shah; Katie Mercaldi; Matthew W Reynolds; Marcia F T Rupnow; Jeffrey Hammond
Journal:  BMC Health Serv Res       Date:  2011-05-31       Impact factor: 2.655

5.  Strategies for Primary Prevention of Coronary Heart Disease Based on Risk Stratification by the ACC/AHA Lipid Guidelines, ATP III Guidelines, Coronary Calcium Scoring, and C-Reactive Protein, and a Global Treat-All Strategy: A Comparative--Effectiveness Modeling Study.

Authors:  Benjamin Z Galper; Y Claire Wang; Andrew J Einstein
Journal:  PLoS One       Date:  2015-09-30       Impact factor: 3.240

6.  Cost-effectiveness of orbital atherectomy compared to rotational atherectomy in treating patients with severely calcified coronary artery lesions in Japan.

Authors:  Jan B Pietzsch; Benjamin P Geisler; Fumiaki Ikeno
Journal:  Cardiovasc Interv Ther       Date:  2017-09-05

7.  Transradial Access for High-Risk Percutaneous Coronary Intervention: Implications of the Risk-Treatment Paradox.

Authors:  Amit P Amin; Sunil V Rao; Arnold H Seto; Manoj Thangam; Richard G Bach; Samir Pancholy; Ian C Gilchrist; Prashant Kaul; Binita Shah; Mauricio G Cohen; Ty J Gluckman; Anna Bortnick; James T DeVries; Hemant Kulkarni; Frederick A Masoudi
Journal:  Circ Cardiovasc Interv       Date:  2021-07-13       Impact factor: 6.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.